PCVX · XBRL financial data

Vaxcyte financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PCVX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	74	78	169	332	477	794
General and administrative	16	25	40	61	93	129
Total operating expenses	90	104	232	468	570	924
Operating income (loss)	(90)	(104)	(232)	(468)	(570)	(924)
Interest income	0	0	8	63	110	120
Interest expense	0	0	0	0	0	—
Other income (expense)	0	4	9	66	106	37
Income tax expense (benefit)	—	—	—	0	0	0
Net income (loss)	(89)	(100)	(223)	(402)	(464)	(767)
Earnings per share, basic USD per share	(3.02)	(1.93)	(3.44)	(4.14)	(3.80)	(5.63)
Earnings per share, diluted USD per share	(3.02)	(1.93)	(3.44)	(4.14)	(3.80)	(5.63)
Weighted average shares, basic millions of shares	30	52	65	97	122	136
Weighted average shares, diluted millions of shares	30	52	65	97	122	136

Fiscal years (PCVX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	386	69	835	397	388	174
Short-term investments	—	177	97	683	1,359	1,387
Prepaid and other current assets	3	10	11	16	41	66
Total current assets	389	256	943	1,096	1,788	1,627
Property and equipment, net	3	8	10	80	198	257
Right-of-use asset	—	28	21	31	72	116
Total assets	393	324	1,006	1,408	3,511	3,003
Accounts payable	30	7	10	15	48	71
Accrued liabilities	4	9	15	60	29	31
Total current liabilities	47	29	41	145	140	206
Lease liability, non-current	—	12	12	22	65	111
Total liabilities	47	40	53	167	205	317
Accumulated deficit	(199)	(299)	(522)	(924)	(1,388)	(2,155)
Total stockholders' equity	346	284	954	1,240	3,306	2,686
Total liabilities and equity	393	324	1,006	1,408	3,511	3,003
Common shares outstanding (cover page) millions of shares	51	56	80	108	129	144

Fiscal years (PCVX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(89)	(100)	(223)	(402)	(464)	(767)
Stock-based compensation	5	11	24	49	85	139
Depreciation and amortization	1	2	3	3	7	16
Net cash from operating activities	(47)	(121)	(171)	(297)	(453)	(656)
Purchases of property and equipment	1	7	6	16	22	14
Net cash from investing activities	(1)	(212)	75	(773)	(2,006)	437
Proceeds from issuing common stock	0	14	97	91	196	—
Net cash from financing activities	375	18	862	640	2,449	2
Net change in cash	327	(316)	766	(437)	(9)	(214)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.